Clinical Study | Open Access
Norma T. Gross, M. L. Arias, M. Moraga, Y. Baddasarow, C. Jarstrand, "Species Distribution and Susceptibility to Azoles of Vaginal Yeasts Isolated Prostitutes", Infectious Diseases in Obstetrics and Gynecology, vol. 2007, Article ID 082412, 5 pages, 2007. https://doi.org/10.1155/2007/82412
Species Distribution and Susceptibility to Azoles of Vaginal Yeasts Isolated Prostitutes
Objective. We investigated the use of miconazole among female prostitutes in Costa Rica as well as the distribution of vaginal yeasts and the susceptibility pattern to azoles of strains obtained from this population. Our intention was to relate a frequent use of miconazole to occurrence of vaginal yeasts resistant to azoles. Methods. Vaginal samples were taken from 277 patients that have previously used azoles. Vaginal swabs were obtained for direct microscopy and culture. Yeast isolates were identified by germ tube test and assimilation pattern. Susceptibility testing was determined using a tablet diffusion method. Results. The number of clinical Candida isolates (one from each patient) was 57 (20.6%). C. albicans was the predominant species (70%), followed by C. parapsilosis (12%), C. tropicalis (5.3%), C. glabrata and C. famata (3.5% each), C. krusei, C. inconspicua and C. guilliermondii (1.7% each). The majority of vaginal Candida isolates were susceptible to ketoconazole (91%), fluconazole (96.5%), and itraconazole (98%). A lower susceptibility of some isolates to miconazole (63%) was observed as compared to the other azoles tested. Moreover, the strains, nonsusceptible to miconazole, were more often obtained from patients that have used this antifungal at least four times within the last year before taking the samples as compared to those with three or less treatments (). Conclusion. An indiscriminate use of miconazole, such as that observed among female prostitutes in Costa Rica, results in a reduced susceptibility of vaginal yeasts to miconazole but not to other azoles.
- J. D. Sobel, “Vaginitis,” New England Journal of Medicine, vol. 337, no. 26, pp. 1896–1903, 1997.
- H. L. Kent, “Epidemiology of vaginitis,” American Journal of Obstetrics and Gynecology, vol. 165, no. 4, pp. 1168–1176, 1991.
- E. A. Sim and C. Hughes, “Candida species from genital sites: their identification and susceptibility to fluconazole,” British Journal of Biomedical Science, vol. 55, no. 4, pp. 264–267, 1998.
- M. S. A. Harady and A. Mustafa, “Yeast flora of the human vagina and effects of antifungal agents on its growth in vitro,” Korean Journal of Mycology, vol. 21, pp. 140–145, 1993.
- F. C. Odds, “Epidemiological shifts in opportunistic and nosocomial Candida infections: mycological aspects,” International Journal of Antimicrobial Agents, vol. 6, no. 3, pp. 141–144, 1996.
- K. H. Abu-Elteen, A. M. M. Abdul Malek, and N. A. Abdul Wahid, “Prevalence and susceptibility of vaginal yeast isolates in Jordan,” Mycoses, vol. 40, no. 5-6, pp. 179–185, 1997.
- W. H. Robertson, “Mycology of vulvovaginitis,” American Journal of Obstetrics and Gynecology, vol. 158, no. 4, pp. 989–991, 1988.
- V. Vidotto, L. Guevara Ochoa, L.-M. Ponce, G. M. Tello, G. R. Prada, and M. Bruatto, “Vaginal yeast flora of pregnant women in the Cusco region of Peru,” Mycoses, vol. 35, no. 9-10, pp. 229–234, 1992.
- R. C. Candido, M. R. T. Toloi, S. A. Franceschini, F. R. Garcia, and E. C. M. Minto, “In vitro activity of antimycotic agents determined by E-test method against vaginal Candida species,” Mycopathologia, vol. 144, no. 1, pp. 15–20, 1998.
- L. Otero, A. Fleites, F. J. Méndez, V. Palacio, and F. Vázquez, “Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 18, no. 1, pp. 59–61, 1999.
- G. Morace, S. Manzara, and G. Dettori, “In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole,” Chemotherapy, vol. 37, no. 1, pp. 23–31, 1991.
- F. Meunier, “Candidiasis,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 8, no. 5, pp. 438–447, 1989.
- A. Spinillo, S. Nicola, L. Colonna, E. Marangoni, C. Cavanna, and G. Michelone, “Frequency and significance of drug resistance in vulvovaginal candidiasis,” Gynecologic and Obstetric Investigation, vol. 38, no. 2, pp. 130–133, 1994.
- J. D. Sobel and J. A. Vazquez, “Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus,” Clinical Infectious Diseases, vol. 22, no. 4, pp. 726–727, 1996.
- K. Schröppel, M. Rotman, R. Galask, K. Mac, and D. R. Soll, “Evolution and replacement of Candida albicans strains during recurrent vaginitis demonstrated by DNA fingerprinting,” Journal of Clinical Microbiology, vol. 32, no. 11, pp. 2646–2654, 1994.
- S. R. Lockhart, B. D. Reed, C. L. Pierson, and D. R. Soll, “Most frequent scenario for recurrent Candida vaginitis is strain maintenance with “substrain shuffling”: demonstration by sequential DNA fingerprinting with probes Ca3, C1, and CARE2,” Journal of Clinical Microbiology, vol. 34, no. 4, pp. 767–777, 1996.
- J. B. Casals, “Tablet sensitivity testing on pathogenic fungi,” Journal of Clinical Pathology, vol. 32, no. 7, pp. 719–722, 1979.
- ROSCO, “Neo-Sensitabs, susceptibility testing,” A/S Rosco, pp. 18.0–18.3, 1998.
- European Committee on Antibiotic Susceptibility Testing, Subcommittee on Antifungal Susceptibility Testing. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts, 1999.
- National Committee for Clinical Laboratory Standards, Reference method for broth dilution antifungal susceptibility testing for yeasts, proposed standard M27-A2, 2002.
- D. J. Finney, R. Latscha, B. M. Bennett, and P. Hsu, Tables for Testing Significance in a 2x2 Contingency Table, Cambridge University Press, Cambridge, Mass, USA, 1963.
- A. W. Fothergill, “Miconazole: a historical perspective,” Expert Review of Anti-Infective Therapy, vol. 4, no. 2, pp. 171–175, 2006.
- P. Marichal, J. Gorrens, M.-C. Coene, L. LeJeune, and H. Vanden Bossche, “Origin of differences in susceptibility of Candida krusei to azole antifungal agents,” Mycoses, vol. 38, no. 3-4, pp. 111–117, 1995.
- T. C. White, K. A. Marr, and R. A. Bowden, “Clinical, cellular, and molecular factors that contribute to antifungal drug resistance,” Clinical Microbiology Reviews, vol. 11, no. 2, pp. 382–402, 1998.
- F. C. Odds, “Resistance of yeasts to azole-derivative antifungals,” Journal of Antimicrobial Chemotherapy, vol. 31, no. 4, pp. 463–471, 1993.
- D. Law, C. B. Moore, H. M. Wardle, L. A. Ganguli, M. G. L. Keaney, and D. W. Denning, “High prevalence of antifungal resistance in Candida spp. from patients with AIDS,” Journal of Antimicrobial Chemotherapy, vol. 34, no. 5, pp. 659–668, 1994.
- K. A. Marr, T. C. White, J.-A. H. van Burik, and R. A. Bowden, “Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation,” Clinical Infectious Diseases, vol. 25, no. 4, pp. 908–910, 1997.
- T. Mori, M. Matsumura, Y. Kanamaru et al., “Myelofibrosis complicated by infection due to Candida albicans: emergence of resistance to antifungal agents during therapy,” Clinical Infectious Diseases, vol. 25, no. 6, pp. 1470–1471, 1997.
Copyright © 2007 Norma T. Gross et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.